Effectiveness of treating NELL1-positive idiopathic membranous nephropathy on clinical outcomes, serum cytokine levels (IL-6, IL-10, IL-2, IL-17), nutritional status, and immune responses

Shuo Li, Yanqiu Yu, Kang LiJournal of Medical Biochemistry 2025 · DOI

TL;DR

This study investigated the effectiveness of combining glucocorticoids (GCs) with tacrolimus (TAC) for treating NELL1-positive idiopathic membranous nephropathy (IMN). The combination therapy demonstrated significant improvements in renal function, glycemic control, lipid profiles, and nutritional status, while also modulating inflammatory cytokine levels, offering a promising and safe treatment option.

What Problem Does This Paper Address?

Idiopathic membranous nephropathy (IMN) is a leading cause of nephrotic syndrome, characterized by immune complex deposition in the kidneys. While glucocorticoids (GCs) are a standard treatment, they often have limitations and can lead to adverse effects, including nutritional disturbances. NELL1-positive IMN is a specific subtype that, while generally having a better prognosis, still requires effective management. The study addresses the need for improved therapeutic strategies that not only enhance clinical outcomes but also mitigate side effects and support the patient's overall health, particularly nutritional status and immune modulation, in the context of NELL1-positive IMN.

Methods

The study employed a randomized controlled trial design involving 84 patients with NELL1-positive IMN. Patients were divided into two groups: a research group receiving GCs (methylprednisolone and prednisone) combined with tacrolimus (TAC), and a control group receiving GCs alone. Treatment duration was six months. Key assessments included:

  • Clinical Parameters: Renal function (serum creatinine, BUN, cystatin C), blood glucose, and lipid profiles (total cholesterol, triglycerides, LDL-C, HDL-C) were measured at baseline and after treatment.
  • Nutritional Status: Assessed using the Nutritional Risk Screening 2002 (NRS 2002) scale and by measuring nutritional proteins (hemoglobin, prealbumin, transferrin, total protein).
  • Immune Response: Serum levels of pro-inflammatory (IL-6, IL-17) and anti-inflammatory (IL-10, IL-2) cytokines were measured using ELISA.
  • Clinical Efficacy: Evaluated based on complete and partial response criteria, including urinary protein levels and renal function.
  • Safety: Adverse reactions were systematically monitored.

Datasets

Not discussed in the paper. The study utilized data collected from patients enrolled in the trial.

Key Insights and Ideas

  • Synergistic Benefits: Combining GCs with TAC not only improved standard clinical markers of IMN but also significantly enhanced nutritional status and modulated the immune response, suggesting a multi-faceted therapeutic advantage.
  • Inflammatory Modulation: The combination therapy effectively reduced pro-inflammatory cytokines (IL-6, IL-17) while increasing anti-inflammatory cytokines (IL-10, IL-2), indicating a shift towards a more balanced immune environment.
  • Nutritional Support: A key finding was the improvement in nutritional protein levels and a reduced risk of malnutrition in the research group, highlighting the importance of addressing nutritional status in IMN management.
  • Safety Profile: The combined therapy demonstrated a comparable safety profile to GCs alone, with no significant increase in adverse events, making it an attractive option for long-term management.

Key Results

  • Clinical Efficacy: While the overall clinical response rate did not differ significantly between groups (83.33% in the research group vs. 76.19% in the control group), the research group showed more significant improvements in renal function, glycemic control, and lipid profiles. HDL-C also increased more in the research group.
  • Nutritional Status: Patients in the research group exhibited significantly better nutritional protein levels (PA, TRF, TP) and a lower risk of malnutrition (as assessed by NRS2002) compared to the control group post-treatment.
  • Cytokine Levels: The research group showed significantly greater reductions in IL-6 and IL-17, and significant increases in IL-10 and IL-2, compared to the control group.
  • Adverse Reactions: The total incidence of adverse reactions was not statistically different between the two groups (26.19% in the research group vs. 19.05% in the control group).

Limitations and Future Work

  • Sample Size: The authors acknowledge that the study had a relatively small sample size, and they recommend further studies with larger cohorts to confirm these findings and refine the treatment protocols.
  • TAC Dosage: The paper mentions the importance of adjusting TAC dosage based on blood drug concentration to maximize therapeutic effect and minimize toxicity, suggesting this as an area for careful clinical management.
  • Further Evaluation: The authors suggest the need to include more indicators to fully evaluate the comprehensive effects of low-dose GCs combined with TAC on NELL1-positive IMN.
  • Long-term Effects: While the study focused on a 6-month treatment period, future research could explore the long-term efficacy and safety of this combination therapy.

Summary updated

Abstract

Combining GCs and TAC is an effective and safe therapeutic option for NELL1-positive IMN. It improves clinical outcomes, maintains nutritional stability, and modulates immune responses without increasing adverse reactions.
BibTeX
@article{li2025effectiveness,
  author = {Shuo Li and Yanqiu Yu and Kang Li},
  title = {{Effectiveness of treating NELL1-positive idiopathic membranous nephropathy on clinical outcomes, serum cytokine levels (IL-6, IL-10, IL-2, IL-17), nutritional status, and immune responses}},
  journal = {Journal of Medical Biochemistry},
  year = {2025},
  doi = {10.5937/jomb0-56892},
}
Figure